strengthening pharmaceutical systems regional monitoring...

Strengthening Pharmaceutical Systems Regional Monitoring System for the Monitoring of the availability of Antimalarial Medications

John Marmion Henrry Espinoza December 2011

Strengthening Pharmaceutical Systems Centro para la Gestión Farmacéutica Management Sciences for Health 4301 North Fairfax Drive, Suite 400 Arlington, VA 22203 USA Teléfono: 703.524.6575 Facsímil: 703.524.7898 E-mail: [email protected]

2

This report is made possible by the generous support of the American people through the U.S.

Agency for International Development (USAID), under the terms of cooperative agreement

number GHN-A-00-07-00002-00. The contents are the responsibility of Management Sciences

for Health and do not necessarily reflect the views of USAID or the United States Government.

About SPS

The Strengthening Pharmaceutical Systems (SPS) Program strives to build capacity within

developing countries to effectively manage all aspects of pharmaceutical systems and services.

SPS focuses on improving governance in the pharmaceutical sector, strengthening

pharmaceutical management systems and financing mechanisms, containing antimicrobial

resistance, and enhancing access to and appropriate use of medicines.

Summary

Recently the Amazon Basin countries have experienced medication supply problems. Changing

malaria incidence and distribution of medications have influenced the ability to program needs

accurately. This report actsas a guide for the regional monitoring system for the availability of

antimalarial medications.

Citation This report can be reproduced with credit given to SPS. Please use the following citation.

Marmion, John, Henrry Espinoza Dec. 2011.Analysis of Antimalarial Medicine Availability in

Amazon Basin Countries. Presented to the United States Agency for International Development

through the Strengthening Pharmaceutical Systems (SPS) Program. Arlington, VA: Management

Sciences for Health

Key Words: Malaria, medication, availability, supply

Strengthening Pharmaceutical Systems

Center for Pharmaceutical Management

Management Sciences for Health

4301 North Fairfax Drive, Suite 400

Arlington, VA 22203 USA

Telephone: 703.524.6575

Fax: 703.524.7898

E-mail: [email protected]

Web: www.msh.org/sps

3

Table of Contents ........................................................................... Error! Bookmark not defined.

Procedure .................................................................................................................................... 4

Introduction ............................................................................................................................. 4

Description of the procedure for the collection and analysis of national and regional

information .............................................................................................................................. 4

Annex 1. Warehouse Report ....................................................................................................... 7

Annex 2: List of Antimalarial Medications ................................................................................ 9

Anex 3: Consolidated National Report ..................................................................................... 10

Annex 4. Technical Report for the national Situation for Antimalarial Availability Ecuador,

2011 (Model) ............................................................................................................................ 12

Annex 5: Consolidated Regional Report .................................................................................. 13

Annex 6: Quarterly Technical Report on the Regional Situation of Antimalarial Availability.

2nd

Quarter 2011 (Model) .......................................................................................................... 15

4

Procedure

Introduction

The Amazon Malaria Iniciative (AMI) with financing from the United States Agency for

International Development supports technical assistance activities to control malaria in countries

that make up the Amazon basin.

Due to the decrease of malaria incidence in the Region of the Americas some countries began to

experience supply management problems around 2008. Overstocked situations were due to

decreased consumption while under stock were due to few manufacturers that were willing to

produce quantities as small as the ones necessary for the incidence in the countries. MSH has

collected data and indicators since 2009 on availability of antimalarials in the central warehouses

and some regional warehouses in the hopes of monitoring the stock situation.

The indicator used in the regional monitoring system is “availability of medications in months

according to consumption”. It is calculated by dividing the units of medication on-hand by the

average monthly consumption/distribution of each warehouse during the previous 12 months.

The indicator can be used to determine months of stock on hand at each warehouse individually.

For past reports, data was presented and discussed with malaria program directors and technical

staff responsible for medication supply in each country. Each country’s information was

consolidated in a regional report. All of the decision makers received an electronic copy of the

regional consolidated report on a quarterly basis.

The information has helped countries to improve medication supply on three levels. Countries

have expedited the process to order medications, redistributed medications in the country and

exchanged/donated medications between countries in the region.

At the August, 2011 regional meeting to improve the supply of antimalarial medications in Lima,

Peru , the participants agreed to strengthen and institutionalize the reporting process. The

agreement included transferring the task of collection, analysis and distribution of the report to a

regional organization. The Direccion Gestion de Medicamentos, Insumos y Drogas (DIDEMID)

(Office for Management of Medications, Supplies and Drugs in English) in Peru offered to

support the process.

This document describes the procedure for the regional monitoring of the availability of

medications.

Description of the procedure for the collection and analysis of national and regional information

1. In the last week of each quarter (December, March, June and September) the director of

the National Malaria Control Program, or designee, in each country requests the

“Warehouse Report” (Annex 1) from all central and regional warehouses. Countries

that already have a regular reporting system should begin this process at step four (4).

5

2. The central and department warehouses record the information on the electronic form

“Warehouse Report”. Detailed instructions for completing this form are detailed in

annex 1. The following items should be taken into consideration when completing the

report.

a. Annex 2 lists the medications needed for the report. The warehouse should mark

‘1’ for medications that are required in the warehouse and a ‘0’ for medications

that are not required based on the Standard Treatment Guidelines.

b. Do not include medications that are expired or in poor condition in the count.

c. Average distribution is obtained by dividing total distribution over the previous

12 months by 121. The distribution should only include distribution within the

country and not include donations to other countries.

3. The central and department warehouses send the “Warehouse Report” to the director of

the NMCP in the first five calendar days of the new quarter. (January, April, July and

October)

4. In the first 10 calendar days of the new semester (January, April, July and October) the

technical team from the NMCP consolidates the data from the central warehouse and

regional warehouses in the form titled “National_Consolidation” (Annex 3). The

completed form is sent to “Dirección General de Medicamentos, Insumos y Drogas

(DIGEMID) in Peru in electronic format. The email address is listed in the footnote

below2.

5. In the first ten days of each new quarter (January, April, July and October) the technical

team from the NMCP of each country analyzes the information and indicators and writes

a national report which is disseminated to the central and department warehouse

managers. There is an sample of the report in Annex 4.

6. Within the first 15 days of the quarter (January, April, July and October), DIGEMID

consolidates and analyzes the information from each country that was received in

electronic format in the report titled “Regional_Consolidation” (Annex 5). DIGEMID

can clarify any discrepancies and unclear information during this time.

7. Within the first 20 calendar days of the new semester, DIGEMID in Peru writes a

technical report highlighting the regional consumption/distribution and supply situation.

See Annex 6 for an example report.

1 Alternatively, if distribution information is not reliable, countries can use two alternatives to estimate average

monthly consumption. Either method is only useful if countries have accurate information. 1) The quantity of

medications consumed by patients in the previous 12 months divided by 12; 2) Morbidity Method: The number of

cases expected to be treated in the next year based on prior data multiplied by treatment scheme divided by 12. 2 DIGEMID, Calle Coronel Odrizola 111, San Isidro, Peru;, Attn: Thalia Chaquilla, Telephone: 51-1-422 8457

Email: [email protected] .

mailto:[email protected]

6

8. DIGEMID distributes the final report the last day of the first month of the new quarter

(January, April, July and October). The report is sent to the authorities of the NMCP,

cooperative technical agencies and other decision makers.

7

Annex 1. Warehouse Report

Ob

ligat

ory

med

icat

ion

bas

ed

on

th

e St

and

ard

Tre

atm

ent

Gu

idel

ines

(1

=ye

s ;

0=

no

)

Un

its

of

med

icat

ion

s av

aila

ble

Ave

rage

Mo

nth

ly

Dis

trib

uti

on

/Co

nsu

mp

tio

n

Mo

nth

s o

f av

aila

bili

ty a

cco

rdin

g

to d

istr

ibu

tio

n/c

on

sum

pti

on

Un

its

to b

e re

ceiv

ed in

th

e n

ext

sem

este

r

001 Artemether-Lumefantrine 20/120 mg X 6 tablet




005 Artesunate 50 mg tablet



008 Artesunate+ SP (Children)

009 Artesunate+ SP (Adolescent)

010 Artesunate+ SP (Adults)

011 Artesunate-Mefloquine 25/55 mg x 3 tablet.



014 Artesunate+Mefloquine 100/220 mg x 6 tablet.

015 Mefloquine 250 mg tablet

016 Sulfadoxine-Pyrimethamine 25/500mg tablet

017 Chloroquine fosfato 150 mg tablet

018 Chloroquine fosfato 100 mg tablet

019 Primaquine fosfato 5 mg tablet

020 Primaquine fosfato 7.5 mg tablet

021 Primaquine fosfato 15 mg tablet

022 Artemether 80 mg/1 ml, 1 ml ampoules

023 Artesunate rectal 50 mg


025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule

026 Clindamycin Hydrochloride 300 mg Capsule

027 Clindamycin Phosphate 150 mg/ mL x 4 mL injectable


029 Clindamycin 75mg/5mL suspension

030 Doxycycline 100 mg Capsule

031 Quinine Hydrochloride 300 mg/ mL x 2 mL injectable


033 Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable


035 Quinine Dihydrochloride 600mg/ml x 2 mL injectable

036 Quinine Sulfate 300mg tablet

037 Quinine Sulfate 500 mg tablet

0

0

#DIV/0!

#DIV/0!

#DIV/0!

#DIV/0!

Seve

re a

nd

Sp

ecia

l Cas

e m

alar

ia t

reat

men

ts

% of STG medications not available

% of STG medications with availability less than the minimum

security stock (3 months)

Number of medications which are part of the Standard

Treatment Guideline (STG) that are available.

Number of medications required in the STG

Ind

icat

ors

% of STG medications which are overstocked (more than 24

months of availability)

% of STG medications available

P. f

alci

par

um

tre

atm

ents

P. v

ivax

trea

tmen

ts

Regional Monitoring System for the Availability of Antimalarial Medications

Warehouse Report

Reporting warehouse/Almacén que

reporta:

Responsible

party/Responsable :

Report Date/Fecha de reporte:

Telephone/Teléfono:

Email/Correo electrónico:

Quarter/Trimestre reportado (1, 2, 3 or 4):

Medications/Medicamentos

Name of Warehouse

8

Instructions:

N° CONCEPTO DESCRIPCIÓN

1 Reporting Warehouse: Put the name of the reporting warehouse

2 Quarter: Put the number of the semester that is being submitted 1 (Jan.-

Mar.), 2 (Apr.-Jun.), 3 (Jul.- Sep.) or 4 (Oct.- Dec.)

3 Report Date: Put the date (day, month and year) the report is completed

4 Responsible Party: Put the name of the person that is completeing the report

5 Telephone and email: Put the telephone and the email address of the warehouse that is

reporting

6 Obligatory medication based

on the Standard Treatment

Guidelines (1=yes ; 0=no)

Put one (1) next to the medications that are obligatory based on the

guidelines for the warehouse. Put zero (0) for medications which

are not obligatory for the warehouse.

7 Units of medication available Put the count of available medications (in units) for all medications

available in the warehouse. If there are medicaions that are

unavailable but should be available in the warehouse, put zero (0).

8 Average monthly

distribution/consumption Put the average distribution or consumption according to the

available data.

9 Units to be received in the next

semester

Complete only for the central warehouse. Put the amount of

medications to be received in the warehouse in the semester that

follows the report.

9

Annex 2: List of Antimalarial Medications

P. f

alci

par

um

tre

atm

ents

















P. v

ivax

trea

tmen

ts 017 Chloroquine Phosphate 150 mg tablet

018 Chloroquine Phosphate 100 mg tablet

019 Primaquine Phosphate 5 mg tablet

020 Primaquine Phosphate 7.5 mg tablet

021 Primaquine Phosphate 15 mg tablet

Seve

re a

nd

Sp

ecia

l Cas

e m

alar

ia t

reat

men

ts

















10

Anex 3: Consolidated National Report

#DIV/0!

Ob

ligat

ory

med

icat

ion

bas

ed o

n

the

Stan

dar

d T

reat

men

t G

uid

elin

es

(1=

yes

; 0

=n

o)

Un

its

of

med

icat

ion

s av

aila

ble

Ave

rage

Mo

nth

ly

Dis

trib

uti

on

/Co

nsu

mp

tio

n

Mo

nth

s o

f av

aila

bili

ty a

cco

rdin

g to

dis

trib

uti

on

/co

nsu

mp

tio

n

Un

its

to b

e re

ceiv

ed in

th

e n

ext

sem

este

r

Un

its

of

med

icat

ion

s av

aila

ble

Ave

rage

Mo

nth

ly

Dis

trib

uti

on

/Co

nsu

mp

tio

n

Mo

nth

s o

f av

aila

bili

ty a

cco

rdin

g to

dis

trib

uti

on

/co

nsu

mp

tio

n

No

of

war

eho

use

s w

ith

no

avai

lab

ility

Ob

ligat

ory

med

icat

ion

bas

ed o

n

the

Stan

dar

d T

reat

men

t G

uid

elin

es

(1=

yes

; 0

=n

o)

Un

its

of

med

icat

ion

s av

aila

ble

Ave

rage

Mo

nth

ly

Dis

trib

uti

on

/Co

nsu

mp

tio

n

Mo

nth

s o

f av

aila

bili

ty a

cco

rdin

g to

dis

trib

uti

on

/co

nsu

mp

tio

n

















017 Chloroquine phosphate 150 mg tablet


019 Primaquine phosphate 5 mg tablet

020 Primaquine phosphate 7.5 mg tablet


















0

0 0 0

0 0 0

#DIV/0! #DIV/0! #DIV/0!

#DIV/0! #DIV/0! #DIV/0!

#DIV/0! #DIV/0! #DIV/0!

#DIV/0! #DIV/0! #DIV/0!

P. f

alci

par

um

tre

atm

ents

P. v

ivax

trea

tmen

tsSe

vere

an

d S

pec

ial C

ase

mal

aria

tre

atm

ents

Report Date/ Fecha de reporte:

Quarter/Trimestre reportado

(1, 2, 3 or 4):

Regional Monitoring System for the Availability of Antimalarial Medications

Central Warehouse/Almacén CentralConsolidated Depart.

Warehouses/Almacenes Depart

Consolidados

One

Consolidated National Report

Number of medications which are part of the

Standard Treatment Guideline (STG) that are

available.

Ind

icat

ors

No. of department warehouses that report

medication availability data


% of STG medications with availability less than the

minimum security stock (3 months)


% of STG medications which are overstocked (more

than 24 months of availability)


Reporting country/ País que

reporta:


No. of departments that

should report

% of departments that

reported availability

data

No. of departments that

reported this quarter

Responsible

party/Responsible :

Telephone/Teléfono:

Email/Correo

electrónico:

11

Instructions


1 Reporting Country Put the name of the country

2 Quarter: Put the number of the semester that is being submitted, ie. 1 (Jan.-

Mar.), 2 (Apr.-Jun.), 3 (Jul.- Sep.) or 4 (Oct.- Dec.)



5 Telephone and email: Put the telephone and the email address of the warehouse that is

reporting

6 Central Warehouse Copy the information from the warehouse reports

6.1.

Obligatory medication based on the

standard treatment Guidelines

(1=Yes, 0=No) Medicamento

Obligatorio de acuerdo a la norma

nacional

Put one (1) next to the medications that are obligatory based

on the guidelines for the warehouse. Put zero (0) for

medications which are not obligatory for the warehouse.

6.2 Units of medication available

Put the count of available medications (in units) for all

medications available in the warehouse. If there are

medicaions that are unavailable but should be available in the

warehouse, put zero (0).

6.3 Average monthly


available data.

6.4 Availability in months according to

distribution/ consumption This column calculates automatically. You do not need to do

anything.

6.5 Units to be received in the next

semester

Complete only for the central warehouse. Put the amount of

medications to be received in the warehouse in the semester

that follows the report.

7 Consolidated Regional Warehouses This column calculates automatically based on the information

provided in the columns for each department warehouses.

8 One/two/Three/… Copy the information from the reports from each department

warehouse

8.1

Obligatory medication based on the

standard treatment Guidelines

(1=Yes, 0=No) Medicamento

Obligatorio de acuerdo a la norma

nacional

Put one (1) next to the medications that are obligatory based

on the guidelines for the warehouse. Put zero (0) for

medications which are not obligatory for the warehouse.


Put the count of available medications (in units) for all

medications available in the warehouse. If there are

medicaions that are unavailable but should be available in the

warehouse, put zero (0).

8.3 Average monthly


available data.

8.4 Availability in months according to

distribution/ consumption This column calculates automatically. You do not need to do

anything.

12

Annex 4. Technical Report for the national Situation for Antimalarial Availability Ecuador, 2011 (Model) Introduction:

Why the data is collected

Utility for decision making

Findings:

Number of warehouses that report

Limitations in the analysis

Availability, stock outs or overstocked situation classified by type of medication. (P. Vivax, P.

Falcipirum, and treatment for special case and severe malaria)

Table 1. Availability of antimalarials in the Central and department warehouses

Obl

igat

ory

med

icat

ion

base

d o

n

the

Stan

dard

Tre

atm

ent

Gui

delin

es (

1=ye

s ;

0=n

o)

Uni

ts o

f m

edic

atio

ns a

vaila

ble

Ave

rage

Mon

thly

Dis

trib

utio

n/C

onsu

mpt

ion

Mon

ths

of a

vaila

bilit

y ac

cord

ing

to d

istr

ibut

ion/

cons

umpt

ion

Uni

ts t

o be

rec

eive

d in

the

nex

t

sem

este

r

Uni

ts o

f m

edic

atio

ns a

vaila

ble

Ave

rage

Mon

thly

Dis

trib

utio

n/C

onsu

mpt

ion

Mon

ths

of a

vaila

bilit

y ac

cord

ing

to d

istr

ibut

ion/

cons

umpt

ion

No

of w

areh

ouse

s w

ith

no

avai

labi

lity

Obl

igat

ory

med

icat

ion

base

d o

n

the

Stan

dard

Tre

atm

ent

Gui

delin

es (

1=ye

s ;

0=n

o)

Uni

ts o

f m

edic

atio

ns a

vaila

ble

Ave

rage

Mon

thly

Dis

trib

utio

n/C

onsu

mpt

ion

Mon

ths

of a

vaila

bilit

y ac

cord

ing

to d

istr

ibut

ion/

cons

umpt

ion

Obl

igat

ory

med

icat

ion

base

d o

n

the

Stan

dard

Tre

atm

ent

Gui

delin

es (

1=ye

s ;

0=n

o)

Uni

ts o

f m

edic

atio

ns a

vaila

ble

Ave

rage

Mon

thly

Dis

trib

utio

n/C

onsu

mpt

ion

Mon

ths

of a

vaila

bilit

y ac

cord

ing

to d

istr

ibut

ion/

cons

umpt

ion

001 Artemether-Lumefantrine 20/120 mg X 6 tablet 0




005 Artesunate 50 mg tablet 1 7,430 672.00 11.06 3594 692 5.19 0 1 1728 275 6.28 1 1866 417 4.47

006 Artesunate 100 mg tablet 0

007 Artesunate 250 mg tablet 0

008 Artesunate+ SP (Children) 0

009 Artesunate+ SP (Adolescent) 0

010 Artesunate+ SP (Adults) 0

011 Artesunate-Mefloquine 25/55 mg x 3 tablet. 1 0 0.00 0.00 10 1 10.00 0 1 10 1 10.00



014 Artesunate+Mefloquine 100/220 mg x 6 tablet. 1 0 0.00 0.00 450 1 450.00 0 1 450 1 450.00

015 Mefloquine 250 mg tablet 1 16,396 206.00 79.59 4404 296 14.88 0 1 854 94 9.09 1 3550 202 17.57

016 Sulfadoxine-Pyrimethamine 25/500mg tablet 0

017 Chloroquine phosphate 150 mg tablet 1 753,937 51,886.00 14.53 31904 5768 5.53 0 1 6104 1718 3.55 1 25800 4050 6.37

018 Chloroquine phosphate 100 mg tablet 0

019 Primaquine phosphate 5 mg tablet 1 40,325 1,890.00 21.34 4823 264 18.27 0 1 3418 47 72.72 1 1405 217 6.47

020 Primaquine phosphate 7.5 mg tablet 0

021 Primaquine phosphate 15 mg tablet 1 235,097 6,304.00 37.29 27422 7801 3.52 0 1 2898 2682 1.08 1 24524 5119 4.79

022 Artemether 80 mg/1 ml, 1 ml ampoules 0

023 Artesunate rectal 50 mg 0

024 Artesunate rectal 100 mg 0

025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule 0 30 1.00

026 Clindamycin Hydrochloride 300 mg Capsule 1 4,232 147.00 28.79 504 2 252.00 0 1 252 1 252.00 1 252 1 252.00

027 Clindamycin Phosphate 150 mg/ mL x 4 mL injectable 0

028 Clindamycin Hydrochloride 150 mg Capsule 0 3,000 0.00

029 Clindamycin 75mg/5mL suspension 0

030 Doxycycline 100 mg Capsule 0

031 Quinine Hydrochloride 300 mg/ mL x 2 mL injectable 0

032 Quinine Hydrochloride 600 mg/ mL x 2 mL injectable 0

033 Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable 0

034 Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable 0 295 11.00

035 Quinine Dihydrochloride 600mg/ml x 2 mL injectable 1 75 10.00 7.50 15 6 2.50 0 1 5 5 1.00 1 10 1 10.00

036 Quinine Sulfate 300mg tablet 1 11,142 138.00 80.74 1160 2 580.00 0 1 452 1 452.00 1 708 1 708.00

037 Quinine Sulfate 500 mg tablet 0

3

8 12 8 12

12 12 8 12

67% 100% 100% 100%

33% 0% 0% 0%

0% 8% 25% 0%

33% 42% 38% 42%


Number of medications which are part of the

Standard Treatment Guideline (STG) that are

available.

Ind

icat

ors

No. of department warehouses that report

medication availability data


% of STG medications with availability less than the

minimum security stock (3 months)


% of STG medications which are overstocked (more

than 24 months of availability)


Central Warehouse/Almacén CentralConsolidated Depart.

Warehouses/Almacenes Depart

Consolidados

One Two

P. f

alci

paru

m t

rea

tmen

tsP.

viv

ax

trea

tmen

tsSe

vere

and

Spe

cial

Cas

e m

alar

ia t

rea

tmen

ts

13

Annex 5: Consolidated Regional Report

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on






































Country 1 Country 2

Seve

re a

nd

Sp

ecia

l Cas

e m

alar

ia t

reat

men

ts

Central Department Central Department Central Department

Country 3

P. f

alci

par

um

tre

atm

ents

Regional Report

Ind

icad

ore

s

Número de almacenes departamentales que reportan

datos de disponibilidad de medicamentos

Número de medicamentos que son parte de la norma

nacional que están disponibles

Número de medicamentos requeridos por la norma

nacional

% de medicamentos en la norma nacional disponibles

% de medicamentos en la norma nacional no

disponibles

% de medicamentos que son parte de la norma

nacional con una disponibilidad menor al stock de

seguridad (menos de 3 meses)

% de medicamentos que son parte de la norma

nacional que están sobre abastecidos (mas de 24

meses)

Medications/Medicamento

Responsible party/

Responsable:

P. v

ivax

trea

tmen

tsRegional Monitoring System for the Availability of Antimalarial Medications

Telephone/ Teléfono:

Email/ Correo electrónico:Report Date/ Fecha de reporte:

Quarter/Trimestre reportado

(1, 2, 3 or 4):

14

Instructions


1 Quarter: Put the number of the semester that is being submitted, ie. 1

(Jan.-Mar.), 2 (Apr.-Jun.), 3 (Jul.- Sep.) or 4 (Oct.- Dec.)



4 Telephone and email: Put the telephone and the email address of the warehouse that

is reporting

5 Country 1, Country 2, Country 3,… Put the name of the country that is completing the report

and copy the data from their national Reports

Country 1: Central


Copy the quantity ( in units) of each medication in the central

warehouse for each country. This information can be found in

the Consolidated National Report from each country. Put a

zero for any medications that are stocked out.

5.2 Months of Availability according to

distribution/ consumption

Copy the Months of availability according to

distribution/consumption in the central warehouse. This

information is obtained in the Consolidated national report of

each country. Use two decimils for this information.

Country 1: Department


Copy the quantity ( in units) of each medication in the

regional warehouses for each country. This information can

be found in the Consolidated National Report from each

country. The report should only include the data ffrom the

consolidated regional column. Put a zero for any medications

that are stocked out.

5.4 Months of Availability according to

distribution/ consumption

Copy the Months of availability according to

distribution/consumption in the regional warehouse. This

information is obtained in the Consolidated national report of

each country. The report should only include the consolidated

warehouse information. Use two decimils for this

information.

15

Annex 6: Quarterly Technical Report on the Regional Situation of Antimalarial Availability. 2nd Quarter 2011 (Model)

Introduction

Rationale for collecting the data on a regional and national level

Countries and agencies that are participating

Utility for decision making

Findings

Number of warehouses that are reporting data

Limitations in the analysis

Availability, stock out or overstock situations classified by type of medication. (P. vivax, P. falcipirum,

or treatments for severe or special case malaria)

Table 1: Availability of antimalarials en central and department warehouses

Country/

País

Number of

medications

that are part

of the

national

STG’s.

Central Level Department Level

% of

medications

available, 2nd

quarter 2011

% of

medications

available, 3rd

quarter, 2011

% of

medications

available, 2nd

quarter 2011

% of

medications

available, 3rd

quarter, 2011

Bolivia 12 66% 66% 100% 100%

Brasil 18 89% 94% nd nd

Colombia 13 92% 54% 91% 69%

Ecuador 9 89% 67% 100% 100%

Perú 8 38% 13% 100% 100%

Annex1:

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

Un

its

of

med

icat

ion

avai

lab

le

Mo

nth

s o

f av

aila

bili

ty

acco

rdin

g to

dis

trib

uti

on

/

con

sum

pti

on

001 Artemether-Lumefantrine 20/120 mg X 6 tablet 2,760 3.19 75,684.00 33.95 3,774 0.18




005 Artesunate 50 mg tablet 7,035 9.98 4,011 13.37






011 Artesunate-Mefloquine 25/55 mg x 3 tablet. 0 0.00 14 3.41 21,210 38.45



014 Artesunate+Mefloquine 100/220 mg x 6 tablet. 0 0.00 672 15.20 29,550 4.60

015 Mefloquine 250 mg tablet 16,314 76.59 5,289 13.88


017 Chloroquine phosphate 150 mg tablet 223,637 5.49 177,393 22.45 1,024,000 21.02 871,200.00 8.95 160,042 0.95


019 Primaquine phosphate 5 mg tablet 34,075 15.18 9,398 6.95 3,376,000 23.97 0.00 0.00 90,022 1.13


021 Primaquine phosphate 15 mg tablet 183,457 18.84 51,396 7.60 5,042,500 9.14 13,176.00 0.07 86,982 0.55

022 Artemether 80 mg/1 ml, 1 ml ampoules 80 0.02

023 Artesunate rectal 50 mg 7,656.00 8.00 1,044 2.70

024 Artesunate rectal 100 mg 16,220 2.30 5,000.00 0.00 0 0.00

025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule 4,092 25.74 1,220 1,220.00 37,936 25.46 0.00 0.00 0 0.00

026 Clindamycin Hydrochloride 300 mg Capsule 47,200 2.95

027 Clindamycin Phosphate 150 mg/ mL x 4 mL injectable 3,000 1.00

028 Clindamycin Hydrochloride 150 mg Capsule 0 0.00 0.00 0.00 0 0.00


030 Doxycycline 100 mg Capsule 75,100 9.50


032 Quinine Hydrochloride 600 mg/ mL x 2 mL injectable 295 29.50

033 Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable 14 0.88 89 29.67 11,620.00 3.80 28,961 15.37

034 Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable 11,002 73.35 2,220 2,220.00 147,100.00 26.48 21,688 11.77



037 Quinine Sulfate 500 mg tablet 243,000 58.80

Country 1 Country 2

Seve

re a

nd

Sp

ecia

l Cas

e m

alar

ia t

reat

men

ts

Central Department Central Department Central Department

Country 3

P. f

alci

par

um

tre

atm

ents

Medications/Medicamento

P. v

ivax

trea

tmen

ts

16

Annex 2 Brazil

Central Departament Central Central Departament Central Departament Central Departament

7 4 11 33

8 12 17 7 10 6 9 1 8

12 12 18 13 13 9 9 8 8

67% 100% 94% 54% 77% 67% 100% 13% 100%

33% 0% 6% 46% 23% 33% 0% 88% 0%

8% 0% 22% 15% 62% 11% 0% 13% 13%

25% 50% 17% 8% 0% 44% 67% 0% 25%

% of national standard treatment guideline

medications with availability less than the

minimum security stock (less than 3months)

% of national standard treatment guideline

medications over stocked (more than 24

months)

Perú

Number of department warehouses that

report data for availability of medications

Number of national standard treatment

guideline medications available

Number of medications required by the

national standard treatment guidelines

% of standard treatment guideline

medications available

% of standard treatment guideline

medications not available

EcuadorIndicators

Bolivia Colombia

strengthening pharmaceutical systems regional monitoring...

Documents